Article
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.
Cancer cell - 15 Feb 2011
Knappskog Stian, Bjørnslett Merete, Myklebust Line M, Huijts Petra E A, Vreeswijk Maaike P, Edvardsen Hege, Guo Yongli, Zhang Xuemei, Yang Ming, Ylisaukko-Oja Sanna K, Alhopuro Pia, Arola Johanna, Tollenaar Rob A E M, van Asperen Christi J, Seynaeve Caroline, Staalesen Vidar, Chrisanthar Ranjan, Løkkevik Erik, Salvesen Helga B, Evans D Gareth, Newman William G, Lin Dongxin, Aaltonen Lauri A, Børresen-Dale Anne-Lise, Tell Grethe S, Stoltenberg Camilla, Romundstad Pål, Hveem Kristian, Lillehaug Johan R, Vatten Lars, Devilee Peter, Dørum Anne, Lønning Per E
Abstract excerpt
MDM2 plays a key role in modulating p53 function. The MDM2 SNP309T > G promoter polymorphism enhances Sp1 binding and has been linked to cancer risk and young age at diagnosis although with conflicting evidence. We report a second MDM2 promoter polymorphism, SNP285G > C, residing on the SNP309G allele. SNP285C occurs in Caucasians only, where 7.7% (95% CI 7.6%-7.8%) of healthy individuals carry the SNP285C/309G...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.